Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

DNA demethylating agents synergize with oncolytic HSV1 against malignant gliomas.

Okemoto K, Kasai K, Wagner B, Haseley A, Meisen H, Bolyard C, Mo X, Wehr A, Lehman A, Fernandez S, Kaur B, Chiocca EA.

Clin Cancer Res. 2013 Nov 1;19(21):5952-9. doi: 10.1158/1078-0432.CCR-12-3588. Epub 2013 Sep 20.

2.

Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus.

Yoo JY, Haseley A, Bratasz A, Chiocca EA, Zhang J, Powell K, Kaur B.

Mol Ther. 2012 Feb;20(2):287-97. doi: 10.1038/mt.2011.208. Epub 2011 Oct 25.

4.

Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma.

Zhang W, Fulci G, Buhrman JS, Stemmer-Rachamimov AO, Chen JW, Wojtkiewicz GR, Weissleder R, Rabkin SD, Martuza RL.

Mol Ther. 2012 Jan;20(1):37-45. doi: 10.1038/mt.2011.187. Epub 2011 Sep 13.

5.

Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase.

Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS.

Cancer Res. 2001 Dec 15;61(24):8743-50.

6.

An armed, YB-1-dependent oncolytic adenovirus as a candidate for a combinatorial anti-glioma approach of virotherapy, suicide gene therapy and chemotherapeutic treatment.

Kostova Y, Mantwill K, Holm PS, Anton M.

Cancer Gene Ther. 2015 Jan;22(1):30-43. doi: 10.1038/cgt.2014.67. Epub 2014 Dec 12.

PMID:
25501992
7.

Copper chelation enhances antitumor efficacy and systemic delivery of oncolytic HSV.

Yoo JY, Pradarelli J, Haseley A, Wojton J, Kaka A, Bratasz A, Alvarez-Breckenridge CA, Yu JG, Powell K, Mazar AP, Teknos TN, Chiocca EA, Glorioso JC, Old M, Kaur B.

Clin Cancer Res. 2012 Sep 15;18(18):4931-41. Epub 2012 Jul 2.

8.
9.

STAT3 activation promotes oncolytic HSV1 replication in glioma cells.

Okemoto K, Wagner B, Meisen H, Haseley A, Kaur B, Chiocca EA.

PLoS One. 2013 Aug 2;8(8):e71932. doi: 10.1371/journal.pone.0071932. Print 2013.

10.

Doxorubicin synergizes with 34.5ENVE to enhance antitumor efficacy against metastatic ovarian cancer.

Bolyard C, Yoo JY, Wang PY, Saini U, Rath KS, Cripe TP, Zhang J, Selvendiran K, Kaur B.

Clin Cancer Res. 2014 Dec 15;20(24):6479-94. doi: 10.1158/1078-0432.CCR-14-0463. Epub 2014 Oct 7.

11.

Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses.

Otsuki A, Patel A, Kasai K, Suzuki M, Kurozumi K, Chiocca EA, Saeki Y.

Mol Ther. 2008 Sep;16(9):1546-55. doi: 10.1038/mt.2008.155. Epub 2008 Jul 22.

12.

The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.

Fujii K, Kurozumi K, Ichikawa T, Onishi M, Shimazu Y, Ishida J, Chiocca EA, Kaur B, Date I.

Cancer Gene Ther. 2013 Aug;20(8):437-44. doi: 10.1038/cgt.2013.38. Epub 2013 Jul 5.

13.

Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy.

Liu TC, Zhang T, Fukuhara H, Kuroda T, Todo T, Martuza RL, Rabkin SD, Kurtz A.

Mol Ther. 2006 Dec;14(6):789-97. Epub 2006 Oct 10.

14.

Cyclophosphamide allows for in vivo dose reduction of a potent oncolytic virus.

Kambara H, Saeki Y, Chiocca EA.

Cancer Res. 2005 Dec 15;65(24):11255-8.

15.

A novel Ad5/11 chimeric oncolytic adenovirus for improved glioma therapy.

Li X, Mao Q, Wang D, Xia H.

Int J Oncol. 2012 Dec;41(6):2159-65. doi: 10.3892/ijo.2012.1674. Epub 2012 Oct 18.

PMID:
23117867
16.

Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.

Reisoli E, Gambini E, Appolloni I, Gatta V, Barilari M, Menotti L, Malatesta P.

Cancer Gene Ther. 2012 Nov;19(11):788-95. doi: 10.1038/cgt.2012.62. Epub 2012 Sep 21.

PMID:
22996742
17.

In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells.

McKenzie BA, Zemp FJ, Pisklakova A, Narendran A, McFadden G, Lun X, Kenchappa RS, Kurz EU, Forsyth PA.

Neuro Oncol. 2015 Aug;17(8):1086-94. doi: 10.1093/neuonc/nou359. Epub 2015 Jan 20.

18.

Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.

Ishida D, Nawa A, Tanino T, Goshima F, Luo CH, Iwaki M, Kajiyama H, Shibata K, Yamamoto E, Ino K, Tsurumi T, Nishiyama Y, Kikkawa F.

Cancer Lett. 2010 Feb 1;288(1):17-27. doi: 10.1016/j.canlet.2009.06.014. Epub 2009 Jul 14.

PMID:
19604626
19.

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.

Lun XQ, Jang JH, Tang N, Deng H, Head R, Bell JC, Stojdl DF, Nutt CL, Senger DL, Forsyth PA, McCart JA.

Clin Cancer Res. 2009 Apr 15;15(8):2777-88. doi: 10.1158/1078-0432.CCR-08-2342. Epub 2009 Apr 7.

20.

Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.

Dong F, Wang L, Davis JJ, Hu W, Zhang L, Guo W, Teraishi F, Ji L, Fang B.

Clin Cancer Res. 2006 Sep 1;12(17):5224-30.

Supplemental Content

Support Center